|Free Dividend Report|
|Stock Splits Calendar|
|ADXS Stock Split History|
|Preferred Stock Newsletter|
|ADXS Options Chain|
|Stock Message Boards|
Advaxis (ADXS) has 2 splits in our ADXS split history database. The first split for ADXS took place on July 15, 2013. This was a 1 for 125 reverse split, meaning for each 125 shares of ADXS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 8 share position following the split. ADXS's second split took place on March 29, 2019. This was a 1 for 15 reverse split, meaning for each 15 shares of ADXS owned pre-split, the shareholder now owned 1 share. For example, a 8 share position pre-split, became a 0.533333333333333 share position following the split.
When a company such as Advaxis conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ADXS split history from start to finish, an original position size of 1000 shares would have turned into 0.533333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Advaxis shares, starting with a $10,000 purchase of ADXS, presented on a split-history-adjusted basis factoring in the complete ADXS split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-44.36%|
|Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the Tumor Microenvironment to enable T cells to eliminate tumors. According to our ADXS split history records, Advaxis has had 2 splits.|
|ADXS Split History Table|
|07/15/2013||1 for 125|
|03/29/2019||1 for 15|
|Healthcare Stock Splits|
|ADXS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: ADXS shares outstanding history